Roivant Sciences Reports First Fiscal Quarter 2021 Financial Results and Provides Business Update prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Roivant Sciences Reports First Fiscal Quarter 2021 Financial Results and Provides Business Update prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Share:
A drug discovery company with ownership stakes in several public and private biopharmaceutical companies is going public with a SPAC deal announced Monday morning.
The SPAC Deal: Roviant Sciences announced a SPAC deal with
Montes Archimedes Acquisition Corp (NASDAQ: MAAC). The deal values the company at an enterprise value of $5 billion.
A $200 million PIPE is backed by companies including Softbank Group Corp., Fidelity Management & Research Co., Sumitomo Dainippon Pharma and
Palantir Technologies Inc (NYSE: PLTR).
Shares of the new company will trade as ROIV on the Nasdaq with an anticipated closing date in the third quarter.
A percentage of current ownership shares will have a three-year lock-up and earn-outs based on $15 and $20 price points. Current Montes Archimedes acquisition shareholders will own 5.6% of the company after the merger.